Traws Pharma, Inc.
$1.39
▼
-1.2%
2026-04-21 09:53:00
www.trawspharma.com
NCM: TRAW
Explore Traws Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$14.12 M
Current Price
$1.39
52W High / Low
$3.27 / $0.97
Stock P/E
—
Book Value
$0.64
Dividend Yield
—
ROCE
-185.49%
ROE
-10.6%
Face Value
—
EPS
$-1.82
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
6
Beta
1.62
Debt / Equity
—
Current Ratio
1.22
Quick Ratio
2.16
Forward P/E
-0.34
Price / Sales
4.16
Enterprise Value
$5.41 M
EV / EBITDA
-0.34
EV / Revenue
1.9
Rating
None
Target Price
$7.25
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 2. | Entera Bio Ltd. | $1.34 | — | $62.47 M | — | -83.6% | -1.08% | $3.22 / $0.91 | $0.28 |
| 3. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
| 4. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 5. | NanoViricides, Inc. | $1.28 | — | $29.59 M | — | -127.59% | -77.53% | $2.23 / $0.85 | $0.51 |
| 6. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 7. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 2.73 M | 0.06 M | 0.06 M | 0.06 M |
| Operating Profit | -4.05 M | -1.25 M | -5.2 M | -5.28 M | -8.54 M |
| Net Profit | -3.96 M | -0.92 M | 21.49 M | -29.92 M | -8.47 M |
| EPS in Rs | -0.5 | -0.11 | 2.69 | -3.74 | -1.06 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0.23 M | 0.23 M | 0.23 M | 0.23 M |
| Operating Profit | -24.91 M | -20.3 M | -19.63 M | -16.5 M |
| Net Profit | -166.52 M | -18.95 M | -18.96 M | -16.16 M |
| EPS in Rs | -20.84 | -2.37 | -2.37 | -2.02 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 24.96 M | 22.68 M | 39.37 M | 55.48 M |
| Total Liabilities | 56.59 M | 12.01 M | 11.06 M | 9.36 M |
| Equity | -31.63 M | 10.67 M | 28.31 M | 46.12 M |
| Current Assets | 24.95 M | 22.66 M | 39.35 M | 55.43 M |
| Current Liabilities | 11.53 M | 9.22 M | 8.05 M | 6.12 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -29.79 M | -17.93 M | -16.29 M | -19.49 M |
| Investing CF | -3.65 M | -0.01 M | 0 M | 0 M |
| Financing CF | 33.98 M | 0 M | 0 M | 55.56 M |
| Free CF | -29.79 M | -17.95 M | -16.29 M | -19.49 M |
| Capex | — | -0.01 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 0% | 0% | 0% | — |
| Earnings Growth % | -778.84% | 0.08% | -17.33% | — |
| Profit Margin % | -73682.74% | -8384.07% | -8391.15% | -7151.77% |
| Operating Margin % | -11022.12% | -8981.42% | -8684.51% | -7299.12% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -11016.81% | -8974.34% | -8678.32% | -7292.92% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-23 | 1:0.04 |
| 2021-05-21 | 1:0.0666667 |